Nine membrane-bound members of the mammalian adenylate cyclase family have been identified. The least characterized and most divergent in sequence of the nine adenylate cyclase isoforms is AC9. Stimulation by G␣ s and inhibition by Ca 2ϩ /calcineurin are two modes of regulation that have been reported for AC9. We explored the possibility of additional modes of regulation of human AC9. We now report that quinpirole activation of the inhibitory G protein-coupled D 2L dopamine receptor inhibits G␣ s stimulation of AC9 by approximately 50%. The effects of quinpirole were reversed by the D 2 antagonist spiperone and by pertussis toxin pretreatment. We also report the first evidence for regulation of AC9 by protein kinase C (PKC). Specifically, phorbol ester activation of PKC significantly attenuated (ϳ50%) G␣ s -stimulated AC9 activity. The effect of PKC activation on AC9 was reversed by the PKC inhibitor bisindolylmaleimide. G␣ s -stimulated cyclic accumulation was reduced more by simultaneous addition of both quinpirole and phorbol 12-myristate 13-acetate than by either drug alone. Additional studies investigated the role of glycosylation on AC9 activity. The results show that blocking glycosylation of AC9 significantly attenuates G␣ s stimulation. In contrast, the ability of PKC and G␣ i/o to negatively regulate AC9 did not seem to be affected by the glycosylation state of AC9. These observations demonstrate the diverse regulatory features of AC9 and the ability of AC9 to integrate multiple signals.
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Adenylate cyclases (EC 4.6.1.1) produce the second messenger cyclic AMP in response to activation of multiple signal transduction pathways. Currently, nine membrane-bound members of the mammalian adenylate cyclase family (AC1-9) have been identified. Various agents regulate the activity of adenylate cyclases, including G proteins, protein kinases, Ca 2ϩ , Mg 2ϩ , and the plant-derived diterpene forskolin (Taussig and Zimmermann, 1998; Chern, 2000; Defer et al., 2000; Sunahara and Taussig, 2002) . All nine membranebound mammal adenylate cyclases are sensitive to stimulation by G␣ s and Mg 2ϩ , and all but AC9 are potently activated by forskolin. The additional factors that regulate adenylate cyclase activity are isoform-specific and mechanistically distinct between isoforms. For example, AC1, AC3, and AC8 are stimulated by Ca 2ϩ /calmodulin, whereas AC5 and AC6 are inhibited by Ca 2ϩ directly acting on these enzymes (Cooper et al., 1995; Guillou et al., 1999) . A number of adenylate cyclase isoforms are also differentially regulated by protein kinases.
For instance, phorbol 12-myristate 13-acetate (PMA) activation of protein kinase C (PKC) stimulates the activity of AC2 and AC7 but inhibits the activity of AC4 and AC6 (Yoshimura and Cooper, 1993) . The diversity in regulation among the different isoforms of adenylate cyclases coupled with the ability of each isoform to integrate numerous signals can make prediction of cyclic AMP signals difficult.
Essential to interpreting and predicting the cyclic AMP response in cells that have a complex pattern of adenylate cyclase expression is identifying the regulatory characteristics of each isoform. The least characterized and most divergent in sequence of the adenylate cyclase isoforms is AC9 (Premont et al., 1996; Patel et al., 2001) . Northern blot, immunocytochemistry, in situ hybridization, and RNA protection analysis indicate that AC9 is expressed widely in the central nervous system as well as in other major organs (Antoni et al., 1998; Hacker et al., 1998; Paterson et al., 2000; Sosunov et al., 2001) . Of particular interest is the relatively abundant expression of AC9 message and protein in the hippocampus, a region important for learning and memory (Antoni et al., 1998) . Stimulation by G␣ s and inhibition by Ca 2ϩ /calcineurin are two modes of regulation that have been reported for AC9 (Paterson et al., 1995 (Paterson et al., , 2000 Antoni et al., 1998; Hacker et al., 1998) . Considering the complex regulation of other adenylate cyclase isoforms, we hypothesized that additional modes of regulation exist for AC9.
In the present study, we identified novel regulatory properties of human AC9. We report that G␣ s stimulation of AC9 is inhibited by the activation of inhibitory G proteins that couple to dopamine D 2L receptor. This inhibition is blocked by the D 2 receptor-selective antagonist spiperone or by pertussis toxin pretreatment. We also report the first evidence for negative regulation of AC9 by PKC. Additional studies investigated the effect of glycosylation on AC9 activity using biochemical and genetic approaches. The results show that blocking glycosylation of AC9 significantly attenuates G␣ s stimulation, whereas the inhibitory effects of PKC and G␣ i/o on AC9 were not altered. These observations demonstrate that AC9 acts as a coincidence detector in a manner similar to that of other adenylate cyclase isoforms and displays unique regulatory properties.
into pBluescript SK(Ϫ). The construct was further subcloned into pcDNA3 after excision with NotI/KpnI from pBluescript SK(Ϫ).
Western Blotting and Immunodetection. Transiently transfected cells were washed once with ice-cold phosphate-buffered saline (137 mM NaCl, 2.68 mM KCl, 10 mM Na 2 PO 4 , and 1.76 mM KH 2 PO 4 , pH 7.4) and placed on ice. Cells were washed once again in membrane isolation buffer (15 mM Na ϩ /Hepes, pH 7.4, 250 mM sucrose, 1 mM dithiothreitol, and 0.3 mM phenylmethylsulfonyl fluoride) and resuspended in the same buffer. Glass-Teflon homogenizers were used to homogenize cells on ice (8 -10 strokes). Homogenates were centrifuged at 750g for 10 min at 4°C. The supernatant was transferred to a fresh tube and centrifuged at 48,900g for 10 min at 4°C to collect the membrane fractions. Pellets were resuspended in sucrose-free membrane isolation buffer. Proteins were separated by polyacrylamide gel electrophoresis on a 7.5% precast Ready-Gels on Mini-PROTEAN 3 Cell electrophoresis systems from Bio-Rad (Hercules, CA). Approximately 50 g of total protein was loaded per sample. The proteins were transferred onto polyvinylidene difluoride membranes for immunodetection with c-myc antibody (Cell Signaling Technology Inc., Beverly, MA).
Membrane Adenylate Cyclase Assay. HEK293 cells stably expressing AC9 were washed once with ice-cold phosphate-buffered saline (as defined above) and placed on ice. Cells were resuspended in deglycosylation buffer (15 mM Na ϩ /Hepes, pH 7.4, 5 mM MgCl 2 , 1 g/ml apoprotinin, and 2 g/ml leupeptin) to produce an approximately 2 mg of protein/ml of cell suspension. Glass-Teflon homogenizers were used to homogenize (8 -10 strokes) the suspended cells on ice. Total protein levels were determined with a BCA protein assay kit (Pierce Chemical, Rockford, IL). Approximately 1 mg of total protein was incubated with 2500 U of peptide:N-glycosidase F (PNGase F) or an equivalent volume of PNGase F storage buffer (50 mM NaCl, 20 mM Tris/HCl, pH 7.4, 5 mM Na ϩ /EDTA, and 50% glycerol) for 45 min at 30°C. Membranes were placed on ice and allowed to cool for at least 15 min. For cyclic AMP accumulation assays, microcentrifuge tubes were placed on ice and reaction buffer was added to each tube (15 mM Na ϩ /Hepes, pH 7.4, 5 mM MgCl 2 , 1 mM 3-isobutyl-1-methyl xanthine, 1 mM ATP, 20 mM phosphocreatine, 125 U of creatine phosphokinase) along with increasing concentrations of the nonhydrolyzable GTP analog 5Ј-guanylylimidodiphosphate (GppNHp). Approximately 30 to 40 g of total protein from chilled membranes was added to each reaction tube on ice bringing the total volume of the reaction mixture to 100 l. The tubes were transferred to 30°C water bath and incubated for 15 min. The reaction was terminated with 200 l of ice-cold 3% trichloroacetic acid, and cyclic AMP levels were quantified as described below.
Cyclic AMP Accumulation Assay. Cells were seeded at densities between 100,000 and 150,000 cells/well in 24-well cluster plates and grown to confluence. The cells were preincubated for 10 min with 200 l/well of assay buffer (Earle's balanced salt solution containing 0.02% ascorbic acid and 2% bovine calf serum). The cells were then placed on ice, and the indicated drugs were added. The cells were then incubated in a 37°C water bath for 15 min. After the incubation, the stimulation media were decanted, and the reaction was terminated with 200 l/well of ice-cold 3% trichloroacetic acid. The 24-well cluster plates were stored at 4°C for up to 1 week before analysis.
Quantification of Cyclic AMP. Cyclic AMP accumulation was quantified using a competitive binding assay as described previously (Watts and Neve, 1996) with minor modifications. Duplicate samples of trichloroacetic acid cell extracts (15 l) were added to reaction tubes. [ 3 H]Cyclic AMP (ϳ1 nM final concentration) and cyclic AMP binding protein (ϳ150 mg) were diluted in cyclic AMP assay buffer (100 mM Tris/HCl, pH 7.4, 100 mM NaCl, and 5 mM EDTA) and then added to each well for a total volume of 550 ml. The tubes were incubated on ice for 2 h and harvested by filtration (Unifilter GF/C; PerkinElmer Life and Analytical Sciences) using a 96-well Filtermate cell harvester (PerkinElmer Life and Analytical Sciences). The filters were allowed to dry, and Microscint O scintillation fluid was added. Radioactivity on the filters was determined using a TopCount Regulatory Characteristics of Type 9 Adenylate Cyclase scintillation/luminescence detector (PerkinElmer Life and Analytical Sciences). Cyclic AMP concentrations in each sample were estimated in duplicate from a standard curve ranging from 0.1 to 300 pmol of cyclic AMP per assay.
Data Analysis. One-way ANOVA followed by Bonferroni's post hoc analysis was used for statistical comparison between multiple stimulation, transfection, and treatment conditions. Statistical analysis was performed using GraphPad Prism (GraphPad Software Inc., San Diego, CA) PKC Inhibits G␣ s -Stimulated AC9 Activity. A number of adenylate cyclases are regulated by protein kinases. Our initial studies aimed at elucidating the regulatory properties of AC9 suggested a possible regulation by PKC. To further characterize PKC regulation of AC9, we explored the effects of the PKC activator PMA on G␣ s -stimulated cyclic AMP accumulation in AC9/D 2L cells. Additional studies examined PKC regulation of two other adenylate cyclase isoforms that exhibit differential regulation by PKC; AC2 (AC2/D 2L ), a PKC-stimulated isoform of adenylate cyclase, and AC1 (AC1/ D 2L ), a PKC-insensitive isoform of adenylate cyclase. Using AC1 and AC2 for comparisons with AC9 provides an additional advantage because these adenylate cyclase isoforms can be selectively stimulated in HEK293 cells by the Ca 2ϩ ionophore A23187 (AC1) and PMA (AC2) (Cumbay and Watts, 2001) . We first characterized the ability of the individual agents to activate adenylate cyclases in the three cell (Cumbay and Watts, 2001 ). To examine whether PKC could regulate G␣ s -stimulated AC9 activity, we measured the effect of PMA on isoproterenolstimulated cyclic AMP accumulation in AC9/D 2L cells. The addition of PMA produced an approximately 60% reduction in the total isoproterenol-stimulated cyclic AMP accumulation (Fig. 2F) . The effects of PMA on isoproterenol-stimulated cyclic AMP accumulation in AC2/D 2L and AC9/D 2L cells were blocked by the PKC inhibitor bisindolylmaleimide (Bis) (Fig.  2 , E and F). Bisindolylmaleimide had no significant effect on isoproterenol-stimulated cyclic AMP levels in HEK cells stably expressing AC9 (Iso, 430 Ϯ 36 pmol/well, n ϭ 4; Iso ϩ Bis, 487 Ϯ 52 pmol/well, n ϭ 3). Additional studies revealed that isoproterenol-stimulated cyclic AMP accumulation in HEK-D 2L cells (Iso, 5.7 Ϯ 1.1 pmol/well, n ϭ 4; Iso ϩ PMA, 7.5 Ϯ 1.4 pmol/well, n ϭ 4) and AC1/D 2L cells was not affected by PMA (Fig. 2D) . The ability of bisindolylmaleimide to attenuate the effect of PMA on AC9 is consistent with the ability of PMA to activate PKC and indicates that PKC can inhibit AC9 activity. That PMA activates both conventional and novel PKCs prompted us to examine the effects of Go6976, an inhibitor of conventional PKCs on AC9 activity. The results of these experiments revealed that concentrations up to 1 M Go6976 failed to inhibit the effects of PMA on AC9 (Table 1 ). In contrast, 1 M Go6976 prevented completely PMA-stimulated AC2 activity, suggesting different classes of PKC isoforms have differential specificity for individual adenylate cyclases (Table 1) . Together, these observations suggest that AC9 is negatively regulated by a novel PKC isoform in HEK293 cells.
Results

D
Because adenylate cyclases can integrate multiple signaling pathways, we explored the ability of AC9 to integrate both G i/o and PKC signals. Isoproterenol-stimulated cyclic AMP accumulation in AC9/D 2L cells was determined in the presence of 10 M quinpirole alone (a concentration that produces maximal inhibition), PMA alone, or both drugs combined. The simultaneous addition of both quinpirole and PMA further reduced the G␣ s -stimulated cyclic accumulation compared with each drug individually (Fig. 3) . The ability of PMA to enhance further maximal inhibition by quinpirole is consistent with independent mechanisms for the concurrent actions of G i/o and PKC on AC9.
Glycosylation State of AC9 Does Not Influence Its Sensitivity to Activation by Forskolin but Determines Its Relative Sensitivity to Activation by G␣ s . Preventing the glycosylation of AC6 has recently been shown to alter its forskolin sensitivity without affecting its regulation by G␣ s (Wu et al., 2001) . We speculated that the relative insensitivity of AC9 to forskolin stimulation could be a consequence of its glycosylation state. To explore this possibility, we first studied the effects of tunicamycin treatment, an agent that blocks N-glycosylation of proteins, on subsequent AC9 activity. In HEK293 cells stably expressing AC9 (HEK-AC9), pre- jpet.aspetjournals.org treatment with tunicamycin (10 g/ml) for 24 h did not significantly alter forskolin-stimulated cyclic accumulation (Fig.  4A) . Because tunicamycin blocks the N-glycosylation of all proteins, the nonspecific effects of tunicamycin may mask the influence of glycosylation on forskolin-stimulated AC9 activity. To directly address the role of glycosylation, we eliminated two potential N-glycosylation sites (N955 and N964) in extracellular loop 6 of AC9 by site-directed mutagenesis. The putative glycosylation sites were mutated to alanine to produce individual (N955A and N964A) and double (N955A/ N964A) glycosylation-deficient mutants of AC9. Western blot analysis of transiently expressed wild-type and glycosylation mutants of AC9 in HEK293 cells revealed two immunoreactive bands (ϳ160 and ϳ130 kDa) for AC9 wild type, N955A, and N964A corresponding to the glycosylated and nonglycosylated forms of AC9 (Fig. 5) . In contrast, examination of HEK293 cells transiently transfected with N955A/N964A revealed only one immunoreactive band (ϳ130 kDa) equivalent to the nonglycosylated form of AC9 (Fig. 5) . Furthermore, the single glycosylation mutants of AC9 (N955A and N964A) seemed to migrate slightly faster than wild-type AC9, indicating that both putative sites are glycosylated (Fig. 5) . Comparison of forskolin-stimulated cyclic AMP accumulation in HEK293 cells transfected with AC9, N955A, N964A, or N955A/N964A demonstrated no significant differences in cyclic AMP levels among the different transfection conditions (Fig. 4B) .
Although the above-mentioned observations suggest that the glycosylation state of AC9 does not influence its sensitivity to forskolin activation, we sought to investigate the role of glycosylation on other functional features of AC9 (i.e., G␣ s , PKC, and G i/o ). Preventing the glycosylation of AC9 by pretreating cells with tunicamycin dramatically reduced isoproterenol-stimulated cyclic AMP accumulation in HEK-AC9 cells (Fig. 6A) . Transient transfection of wild-type and glycosylation-deficient mutants of AC9 in HEK293 cells followed by isoproterenol stimulation revealed a significantly reduced cyclic AMP accumulation in cells expressing N955A/N964A, but no significant reduction in the cyclic AMP levels were observed in N955A-or N964A-expressing cells compared with wild-type AC9-expressing cells (Fig. 6 , B and C). Doseresponse curves for isoproterenol stimulation of AC9 activity indicated a reduced maximal cyclic AMP accumulation in tunicamycin-treated or N955A/N964A-expressing cells compared with vehicle-treated or AC9-expressing cells, respectively (Fig. 6, A and B) . However, the EC 50 (wild type AC9 33 Ϯ 5.2 nM, n ϭ 6; N955A/N964A 38 Ϯ 3.8 nM, n ϭ 6) for isoproterenol-stimulated activity did not seem to be affected by the glycosylation state of AC9. We also sought to examine how the glycosylation state of AC9 could affect the two novel modes of regulation identified in the current study. Because glycosylation alters G␣ s responsiveness (Fig. 6) , the data examining PKC and G i/o regulation were normalized to isoproterenol-stimulated cyclic AMP accumulation observed after transfection with AC9, N955A, N964A, or N955A/N964A as indicated. The addition of PMA to HEK293 cells transiently expressing wild-type or glycosylation-deficient AC9 mutants inhibited isoproterenol-stimulated cyclic AMP accumulation to the same extent (ca. 50%) independent of the glycosylation state (Fig. 7A) . Similarly, maximal D 2L receptor-mediated inhibition of G␣ s -activated N955A/N964A activity was commensurate with that of wild-type AC9 (Fig.  7B) .
Apart from the direct effect of glycosylation, reduced trafficking to the plasma membrane may explain the reduced G␣ s -stimulated cyclic AMP accumulation in N955A/N964A-expressing cells. Decreased trafficking to the plasma membrane would reduce membrane adenylate cyclase levels and consequently reduce G␣ s -stimulated cyclic AMP levels. To address this possibility, we used membranes from HEK-AC9 cells, circumventing the potential for reduced trafficking of glycosylation-deficient mutants of AC9. This method also allows for the direct examination of the role of glycosylation with the use of a degylcosidase. Treating membranes with (Fig. 8) . Combined, the data presented here indicate that the glycosylation state of AC9 selectively influences its activation by G␣ s .
Discussion
Adenylate cyclase type 9 is a unique member of the mammalian adenylate cyclase family. It is the most divergent in sequence and unlike the other isoforms, AC9 is relatively insensitive to activation by forskolin (Hacker et al., 1998; Yan et al., 1998) . Little is known about the regulatory properties of AC9 apart from activation by G␣ s and inhibition by calcineurin (Antoni et al., 1998; Hacker et al., 1998; Paterson et al., 2000) . The data presented in this study demonstrate that activation of inhibitory G protein-coupled D 2L dopamine receptor significantly inhibits G␣ s -stimulated AC9 activity. We also provide evidence that phorbol ester activation of a novel PKC significantly attenuates G␣ s -stimulated AC9 activity. Furthermore, examining the consequence of glycosyl- 8 . G␣ s stimulation of AC9 after treatment with PNGase F. Membranes from HEK293 cells stably overexpressing AC9 were collected as described under Materials and Methods. Approximately 1 mg of total protein was incubated with 2500 U of PNGase F or an equivalent volume of PNGase F storage buffer (Vehicle) for 45 min at 30°C. Cyclic AMP accumulation was stimulated by adding increasing concentrations of the nonhydrolyzable GTP analog GppNHp and incubating membranes for 15 min in 30°C water bath. The reaction was terminated with 200 l/well of ice-cold 3% trichloroacetic acid and cyclic AMP accumulation was determined as described under Materials and Methods. ‫,ء‬ p Ͻ 0.05 compared with GppNHp-stimulated cyclic AMP accumulation in PNGase F-treated membranes (one-way ANOVA with Bonferroni's post hoc test). jpet.aspetjournals.org ation on AC9 activity reveals that the glycosylation state of AC9 can selectively influence regulation by G␣ s .
Although G␣ s activation is common to all adenylate cyclase isoforms, regulation by inhibitory G proteins (G i/o ) is variable among the different isoforms. The ␣-subunit of G i/o potently inhibits AC5 and AC6 but does not alter the activity of AC2 or AC8 (Chen and Iyengar, 1993; Taussig et al., 1993; Nielsen et al., 1996) . Further illustrating the complication of G i/o regulation of adenylate cyclases, AC2 can be conditionally activated by ␤␥-subunits released from G i/o proteins (Tang and Gilman, 1991; Lustig et al., 1993) . Initial evaluation, by Hacker et al. (1998) , of the ability of G i/o to inhibit isoproterenol-stimulated AC9 activity suggested that AC9 is insensitive to modulation by inhibitory G proteins. These initial studies of AC9 regulation by G i/o were characterized in HEK293 cells expressing the human clone of AC9 used in the current study. They demonstrated that activation of endogenously expressed somatostatin receptors does alter G␣ sstimulated AC9 activity. Although endogenously expressed somatostatin receptors have been shown to inhibit Ca 2ϩ -stimulated AC1 activity in HEK293 cells, the extent of inhibition observed was notably lower than that produced by dopamine D 2L receptors overexpressed in the same cell line (Nielsen et al., 1996) . One plausible explanation for the difference in the degree of inhibition is that the receptor levels of an exogenously expressed receptor are likely to be much higher relative to the endogenous receptors. We reasoned that if AC9 is not potently inhibited by G i/o , expression of D 2L receptors would allow us to detect inhibition of AC9. In the current study, we used HEK293 cells expressing both AC9 and D 2L to investigate G i/o inhibition of AC9. We show that activation of D 2L receptors significantly attenuates G␣ s -stimulated AC9 activity. Inhibition by D 2L receptors does not completely block stimulated AC9 activity but reduces cyclic AMP to approximately 50% of maximal levels. This is consistent with the view that AC9 is not potently inhibited by G i/o . The ability of pertussis toxin to block inhibition of AC9 suggests that the D 2L receptor acts through a G i/o pathway to mediate its inhibition of AC9. It should be noted, however, that this set of experiments does not distinguish between the ␣-or ␤␥-subunits in mediating the inhibitory effects of D 2L . Although, reconstitution studies with membranes from mouse AC9-infected Sf9 cells, purified constitutively active G␣ s , and purified ␤␥-subunits indicate that ␤␥-subunits do not significantly alter G␣ s -stimulated AC9 activity (Premont et al., 1996) . These data imply that the inhibitory effects of D 2L on AC9 activity are the consequence of the ␣-subunit of G i/o acting on AC9.
Protein phosphorylation is a significant regulatory mechanism for adenylate cyclases. All adenylate cyclases, with the exception of AC9, have previously been shown to be regulated by one of three classes of protein kinases: protein kinase A, Ca 2ϩ /calmodulin-dependent protein kinases, and PKC (Sunahara and Taussig, 2002) . Evidence from several reports demonstrates that protein kinase regulation of adenylate cyclase can occur through direct phosphorylation (Jacobowitz and Iyengar, 1994; Wayman et al., 1996; Wei et al., 1996; Chen et al., 1997; Lai et al., 1999; Lin et al., 2002) . We have identified in this study an inhibitory mode of regulation of AC9 by PKC. To demonstrate that the PMA effects on AC9 resulted from the activation of PKC, we included in this study adenylate cyclases that exhibit differential regulation by PKC, AC1 and AC2. Consistent with the potent and relatively specific activation of PKC by PMA (100 nM), no PKCindependent effects of PMA on cyclic AMP accumulation were observed. Furthermore, the results obtained with the PKC inhibitor bisindolylmaleimide agree with these observations.
One of the well characterized regulatory features of AC9 is inhibition of basal activity by Ca 2ϩ in calcineurin-dependent manner (Paterson et al., 1995 (Paterson et al., , 2000 . Calcineurin is a protein phosphatase that has been shown to be coexpressed with AC9 in postsynaptic terminals of some hippocampal and cortical neurons (Sosunov et al., 2001) . Observations that a protein kinase and phosphatase can regulate AC9 activity could indicate that both calcineurin and PKC target the same residues on AC9. This seems unlikely because both activation of PKC and calcineurin results in the inhibition of AC9. It is probable that another protein kinase(s) can also act on AC9 to modulate its activity. Considering that calcineurin inhibits basal AC9 activity it is likely that AC9 is tonically phosphorylated by a yet-to-be identified protein kinase.
Coincidence detection is an important feature of adenylate cyclases and is essential for cells that receive numerous signals simultaneously (Anholt, 1994; Mons and Cooper, 1994; Xia and Storm, 1997; Mooney et al., 1998) . The cyclic AMP signaling pathway is present in a wide range of cell types, and expression of multiple isoforms of adenylate cyclase within a cell can facilitate the integration of numerous signals (Chern, 2000) . Having identified two novel modes of regulation for AC9, we examined the ability of this adenylate cyclase to perform as a coincidence detector. G␣ s -stimulated AC9 activity in HEK-AC9 cells was less when treated with quinpirole and PMA than when treated with quinpirole or PMA alone. Analogous to the regulatory features of other adenylate cyclase isoforms, AC9 exhibits the ability to integrate multiple signals.
Glycosylation of proteins has been shown to influence stability, transport to the plasma membrane, and protein function (Boege et al., 1988; Khanna et al., 2001; Martinez-Maza et al., 2001 ). An alignment of the nine membrane-bound adenylate cyclase isoforms indicates that potential N-glycosylation sites, localized to the fifth and/or sixth extracellular loops, are conserved in each isoform (Wu et al., 2001) . A number of adenylate cyclase isoforms (i.e., AC2, AC3, AC6, AC8, and AC9) have been shown to be glycosylated; however, the functional consequence of glycosylation seems to differ between isoforms (Cali et al., 1996; Premont et al., 1996; Wei et al., 1996; Bol et al., 1997; Wu et al., 2001) . Blocking the glycosylation of AC6 reduces inhibition by PKC phosphorylation and alters the response to inhibitory G protein-coupled receptors without significantly affecting the maximal response to G␣ s stimulation (Wu et al., 2001) . In contrast, AC9 stimulation by G␣ s is attenuated, whereas PKC and G i/o inhibition seem to be unaffected by the glycosylation state of AC9 under the conditions used in this study. Despite the functional differences in response to deglycosylation, glycosylation likely mediates its effects by influencing the structure of adenylate cyclases, although the location of the glycosylation sites could lead to different structural consequences. The two N-glycosylation sites of AC9 are located on the sixth extracellular loop, whereas AC6 has glycosylation sites on the fifth and sixth loops. We have shown in this study that both sites on AC9 are glycosy-lated; however, single-site glycosylation deficient mutants of AC9 do not exhibit significant changes in response to G␣ s or PKC. Unfortunately, similar studies examining the role of the individual glycosylation sites on the fifth and sixth extracellular loop of AC6 have not been reported. The current study provides additional evidence for unique functional consequences of glycosylation on adenylate cyclase function.
Cyclic AMP has been demonstrated to have an essential role in the learning and memory process. High-frequency stimulation of hippocampal neurons establishes long-term potentiation, a molecular model for learning and memory, and causes Ca 2ϩ influx resulting in Ca 2ϩ /calmodulin-dependent increases in cyclic AMP (Mons et al., 1999; Chern, 2000) . This increase in cyclic AMP has been demonstrated to be required for long-term memory. Mice lacking the two Ca 2ϩ / calmodulin-activated adenylate cyclases expressed in the hippocampus, AC1 and AC8, do not exhibit normal latephase long-term potentiation and long-term memory (Mons et al., 1999) . In addition to the two Ca 2ϩ -stimulated adenylate cyclases, two Ca 2ϩ -inhibited isoforms are also expressed in the hippocampus: AC6, which is directly inhibited by Ca 2ϩ , and AC9, which is inhibited by Ca 2ϩ in a calcineurindependent manner. It has been suggested that fine-tuning the cyclic AMP pathway by Ca 2ϩ -dependent or -independent factors, possibly G i/o or PKC, may play a role in facilitating learning and memory (Chern, 2000) . That AC6 and now AC9 are known to be inhibited by PKC and G i/o presents an opportunity for fine-tuning of cyclic AMP signaling that should be explored in vivo.
